Poster Presentations S67 inhibit the expression of HBsAg, HBeAg, and HBV DNA replication in vitro in a dose-dependent manner. A RT-PCR analysis indicated that the expression of cccDNA changed significantly in the MP treatment group compared to the control group and in a dose and time-dependent manner. FK506 did not the same role in the levels of HBVDNA and cccDNA. However, FK506 at different nontoxic contrations showed no significant inhibitory effect on the levels of HBsAg HBeAg and HBVDNA. Conclusion: Our study identified MP does-and time-dependently inhibits the HBV replication in vitro, and found that cccDNA for this inhibitory effect. FK506 does not exercise similar effects. λ, d, b, a, p, k, u, k2, k3, k4 where the meanings of λ, d, b, a, p, k, u are the same as those given in Nowak's model, k2 represents the curative effect, k3, k4 are relevant to the immune, we choose {λ, d, b, a, p, u, k3, k4 = 4.621e5, 6.9e-3, 6.508e-4, 6.9e-3, 0.058, 0.35, 0.95, 0.036}
PP-063 NOTCH 1 regulates FOXP3 regulatory T cells and deranged TGF-β signaling in progressive stages of hepatitis B infection
Nirupama λ, d, b, a, p, k, u, k2, k3, k4 where the meanings of λ, d, b, a, p, k, u are the same as those given in Nowak's model, k2 represents the curative effect, k3, k4 are relevant to the immune, we choose {λ, d, b, a, p, u, k3, k4 = 4.621e5, 6.9e-3, 6.508e-4, 6.9e-3, 0.058, 0.35 Background:To study the effect of adeforvir dipivoxil on HBcAgspecific cytotoxic T cells in patients with chronic hepatitis B (CHB). Methods: Frequency of circulating HBcAg-specific cytotoxic T cells from 11 HLA-A2+ patients with chronic hepatitis B were studied longitudinally before and after adeforvir dipivoxil therapy by HLA-A2/peptide tetramer staining. Results: Frequencies of HBcAg-specific cytotoxic T cells were no significant differences between before and after adeforvir dipivoxil therapy. Conclusion: There is probably no effect effect of adeforvir dipivoxil on HBcAg-specific cytotoxic T cells in patients with CHB.
PP-067 Effects of interventional therapy for primary liver carcinoma on the liver function of patients
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Background: The effects of interventional therapy for hepato-
